Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Edgewise news feed on Stock Titan aggregates company announcements, press releases, and other coverage related to its clinical programs, corporate developments, and financial updates.
Investors and observers following EWTX news will see regular updates on the company’s lead product candidates. These include sevasemten, an orally administered first-in-class fast skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophies; EDG-7500, a cardiac sarcomere modulator in Phase 2 development for hypertrophic cardiomyopathy; and EDG-15400, a cardiac sarcomere modulator in Phase 1 development for heart failure. News items often describe trial progress, such as enrollment status, interim results, and plans for pivotal studies, as well as interactions with regulators.
The Edgewise news stream also features corporate and governance updates, including board and executive appointments, inducement equity grants under Nasdaq Listing Rules, participation in major healthcare and investor conferences, and periodic financial results. These disclosures provide context on how the company is building its organization and funding its research and development activities.
By monitoring this page, readers can review historical and recent EWTX news related to muscular dystrophy and cardiovascular programs, clinical milestones, and corporate actions as reported by the company in its public communications.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants made March 31, 2026: 72,000 stock options were awarded to four new non‑executive employees under the 2024 Inducement Equity Incentive Plan.
Each option has an exercise price of $32.46 (closing price on the grant date) and vests 25% after one year, then 1/48th monthly thereafter, subject to continued service, granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Edgewise (Nasdaq: EWTX) reported long-term MESA open-label extension data for investigational sevasemten in Becker muscular dystrophy showing functional stabilization through 3.5 years on NSAA versus predicted declines from Becker natural history. Key numeric divergences: CANYON +0.1 vs predicted -2.9 (2 years) and ARCH +0.1 vs predicted -5.3 (3.5 years). Nearly 99% of eligible prior trial participants enrolled in MESA. Sevasemten maintained a favorable long-term safety profile. The placebo-controlled pivotal cohort, GRAND CANYON, is expected to read out in 4Q 2026, after which the company may pursue a marketing application if results are positive.
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET. The company said the presentation will be webcast live and available for replay for a limited time.
Investors can find the webcast link on the Edgewise Events & Presentations page and are advised to connect several minutes early to ensure a timely connection.
Edgewise Therapeutics (Nasdaq: EWTX) will present new clinical and natural history data on sevasemten for Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference in Orlando, March 8–11, 2026.
Edgewise will host a lunch forum on March 9 and showcase multiple scientific posters from March 8–10, including MESA open-label extension results and CANYON cardiac biomarker analyses. Presentations will be posted on the company website after the conference.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants on February 27, 2026, issuing options to purchase 51,000 shares to three new non-executive employees under its 2024 Inducement Equity Incentive Plan.
Options carry an exercise price of $30.44 equal to the closing price on the grant date and vest 25% after one year then monthly at 1/48th thereafter, subject to continued service, granted under Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) reported Q4 and full-year 2025 results, highlighted by strong program progress and $530.1M cash at year-end. Key near-term catalysts include CIRRUS-HCM 12-week Part D data and EDG-15400 Phase 1 topline in H1 2026, and pivotal GRAND CANYON sevasemten data in Q4 2026.
R&D and G&A expenses rose in Q4, and net loss was $50.2M ($0.47/share). The company plans an NDA timeline for sevasemten in H1 2027, pending results.
Edgewise Therapeutics (Nasdaq: EWTX) announced that COO Behrad Derakhshan, Ph.D. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 3:00 pm ET. The presentation will be webcast live and available for limited replay via the company Events & Presentations page.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity grants made January 30, 2025 to seven new non‑executive employees totaling 198,250 stock options under its 2024 Inducement Equity Incentive Plan.
Options have an exercise price of $28.15 (equal to the closing price on the grant date) and vest 25% after one year then 1/48th monthly thereafter, subject to continued service, granted pursuant to Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) outlined 2026 priorities including pivotal trial milestones, late‑stage cardiology readouts, and regulatory planning. The company completed enrollment in the GRAND CANYON pivotal cohort for sevasemten and expects top‑line results in Becker muscular dystrophy in Q4 2026, with a planned U.S. NDA submission in H1 2027. For cardiology programs, Edgewise expects CIRRUS‑HCM 12‑week data for EDG‑7500 in H1 2026 and aims to initiate Phase 3 in obstructive and nonobstructive HCM in H2 2026. The company raised approximately $200 million net proceeds from an April 2025 follow‑on offering to fund these programs. Management presented these updates at J.P. Morgan on Jan 13, 2026.
Edgewise Therapeutics (Nasdaq: EWTX) announced that Kevin Koch, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 8:15 am PT (11:15 am ET). The presentation will be webcast live and available for replay for a limited time on the company's Events & Presentations page. Attendees are advised to connect several minutes early to ensure a timely connection.